[go: up one dir, main page]

DE69700983D1 - Ligandgerichtete enzyme-prodrug therapie - Google Patents

Ligandgerichtete enzyme-prodrug therapie

Info

Publication number
DE69700983D1
DE69700983D1 DE69700983T DE69700983T DE69700983D1 DE 69700983 D1 DE69700983 D1 DE 69700983D1 DE 69700983 T DE69700983 T DE 69700983T DE 69700983 T DE69700983 T DE 69700983T DE 69700983 D1 DE69700983 D1 DE 69700983D1
Authority
DE
Germany
Prior art keywords
prodrug therapy
enzyme prodrug
targeted enzyme
ligand targeted
ligand
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69700983T
Other languages
English (en)
Inventor
Caroline Joy Springer
Richard Marais
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cancer Research Campaign Technology Ltd
Original Assignee
Cancer Research Campaign Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Research Campaign Technology Ltd filed Critical Cancer Research Campaign Technology Ltd
Application granted granted Critical
Publication of DE69700983D1 publication Critical patent/DE69700983D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
    • A61K47/67—Enzyme prodrug therapy, e.g. gene directed enzyme drug therapy [GDEPT] or VDEPT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nanotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Invalid Beds And Related Equipment (AREA)
DE69700983T 1996-01-26 1997-01-24 Ligandgerichtete enzyme-prodrug therapie Expired - Lifetime DE69700983D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9601640.7A GB9601640D0 (en) 1996-01-26 1996-01-26 Ligand directed enzyme prodrug therapy
PCT/GB1997/000221 WO1997026918A2 (en) 1996-01-26 1997-01-24 Ligand directed enzyme prodrug therapy

Publications (1)

Publication Number Publication Date
DE69700983D1 true DE69700983D1 (de) 2000-01-27

Family

ID=10787646

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69700983T Expired - Lifetime DE69700983D1 (de) 1996-01-26 1997-01-24 Ligandgerichtete enzyme-prodrug therapie

Country Status (9)

Country Link
EP (1) EP0876160B1 (de)
JP (1) JP2000504218A (de)
AT (1) ATE187890T1 (de)
AU (1) AU709238B2 (de)
DE (1) DE69700983D1 (de)
GB (1) GB9601640D0 (de)
NZ (1) NZ326436A (de)
WO (1) WO1997026918A2 (de)
ZA (1) ZA97657B (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9709421D0 (en) 1997-05-10 1997-07-02 Zeneca Ltd Chemical compounds
CA2322664A1 (en) * 1998-03-06 1999-09-10 Oxford Biomedica (Uk) Limited Enhanced prodrug activation
US6174687B1 (en) 1999-02-26 2001-01-16 The Burnham Institute Methods of identifying lung homing molecules using membrane dipeptidase
US6232287B1 (en) 1998-03-13 2001-05-15 The Burnham Institute Molecules that home to various selected organs or tissues
ES2313779T3 (es) 1998-03-13 2009-03-01 The Burnham Institute Moleculas que migran a diversos organos o tejidos seleccionados.
GB9907414D0 (en) 1999-03-31 1999-05-26 Cancer Res Campaign Tech Improvements relating to prodrugs
US6656718B2 (en) 2000-07-07 2003-12-02 Cancer Research Technology Limited Modified carboxypeptidase enzymes and their use
EP2283868B1 (de) 2002-07-15 2016-03-30 Board of Regents, The University of Texas System Peptide mit Bindung an Phosphatidylethanolamine und ihre Verwendung bei der Behandlung von Virusinfektionen und Krebs
GB0220319D0 (en) 2002-09-02 2002-10-09 Cancer Res Campaign Tech Enzyme activated self-immolative nitrogen mustard drugs
DK2219672T3 (en) 2007-11-09 2016-05-17 Peregrine Pharmaceuticals Inc The anti-VEGF antibody compositions and methods
US10947270B2 (en) * 2015-08-27 2021-03-16 National Yang-Ming University Targeted prodrug cytosine deaminase fusion carrier and application thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308483D0 (en) * 1983-03-28 1983-05-05 Health Lab Service Board Secretion of gene products
ES2180535T3 (es) * 1991-02-22 2003-02-16 American Cyanamid Co Identificacion de un nuevo gen de tirosina quinasa receptora humana.
JP3734262B2 (ja) * 1993-03-25 2006-01-11 メルク エンド カンパニー インコーポレーテッド 血管内皮細胞増殖因子阻害剤
HUT74451A (en) * 1993-07-15 1996-12-30 Cancer Res Campaign Tech Prodrugs of protein tyrosine kinase inhibitors, systems contg. them and process for preparing them
GB9315494D0 (en) * 1993-07-27 1993-09-08 Springer Caroline Improvements relating to prodrugs
JPH09510352A (ja) * 1994-03-15 1997-10-21 プリズム ファーマシューティカルズ，インコーポレイティド 遺伝子療法及び前部の眼疾患のためのヘパリン結合成長因子
WO1996006641A1 (en) * 1994-08-29 1996-03-07 Prizm Pharmaceuticals, Inc. Conjugates of vascular endothelial growth factor with targeted agents
EP0802801A2 (de) * 1994-12-30 1997-10-29 Chiron Corporation Verfahren und zusammensetzungen zur in vivo behandlung der festen tumoren

Also Published As

Publication number Publication date
WO1997026918A2 (en) 1997-07-31
AU709238B2 (en) 1999-08-26
JP2000504218A (ja) 2000-04-11
ATE187890T1 (de) 2000-01-15
GB9601640D0 (en) 1996-03-27
AU1453097A (en) 1997-08-20
ZA97657B (en) 1997-08-01
NZ326436A (en) 1999-03-29
EP0876160B1 (de) 1999-12-22
WO1997026918A3 (en) 1997-10-23
EP0876160A2 (de) 1998-11-11

Similar Documents

Publication Publication Date Title
ES2143641T3 (es) Expresion en superficie de una enzima en la terapia genica a base de promedicamentos.
AU1916995A (en) 4-amino derivatives of mycophenolic acid with immunosuppressant activity
AU3649397A (en) Precise efficacy assay methods for active agents including chemotherapeutic agents
AU1917095A (en) 6-substituted mycophenolic and derivatives with immunosuppressive activity
AR032293A1 (es) Estuche farmaceutico
TR199901949T2 (xx) Lemfositik t�m�rler i�in �areler.
DE69700983D1 (de) Ligandgerichtete enzyme-prodrug therapie
AU8239298A (en) Nucleotide-comprising composition
MX9805939A (es) Formas solidas de administracion, de liberacion instantanea y procesos para su produccion.
IT1270618B (it) Proteine ad attivita' antitumorale
EP0666313A3 (de) Telomerase als Ziel in der Gentherapie des Krebs.
AU1747295A (en) 4-amino 6-substituted mycophenolic acid and derivatives with immunosuppressive activity
AU1875395A (en) 4-amino derivatives of 5-substituted mycophenolic acid
WO1999064065A3 (en) Tumour therapy and imaging
BR0008791A (pt) Derivados anticonvulsivos, úteis no tratamento de tremor essencial
AU1287001A (en) Product comprising at least a no synthase inhibiting substance associated with at least a phospholipase a2 inhibiting substance
TR200000728T2 (tr) Kronik hepatit C' nin tedavisinde IFN-alfa ve amantadin kullanımı.
PT980379E (pt) Oligonucleotidos quimericos e sua utilizacao
ZA977895B (en) Transdermal therapeutic system having an active compound combination comprising oestriol.
MX9708111A (es) Lipidos cationicos para terapia genica.
DK1800664T3 (da) Farmaceutiske formuleringer til parenteral indgivelse indeholdende epothilon

Legal Events

Date Code Title Description
8332 No legal effect for de